Targeted therapies in non-small cell lung cancer: Emerging oncogene targets following the success of epidermal growth factor receptor

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 110-125

  Berge, Eamon M ^a   Doebele, Robert C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84894414819     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.006     Document Type: Article

References (139)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
2. A. Jemal, M.M. Center, C. DeSantis, and E.M. Ward Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19 8 2010 1893 1907
3. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage. 2009 Populations). Available from URL: http://seer.cancer. gov/csr/1975-2009-pops09/.
4. P. Goldstraw, J. Crowley, and K. Chansky et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 8 2007 706 714
5. A. Sandler, R. Gray, and M.C. Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2006 2542 2550
6. G. Scagliotti, N. Hanna, and F. Fossella et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 3 2009 253 263
7. J.H. Schiller, D. Harrington, and C.P. Belani et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2 2002 92 98
8. G.V. Scagliotti, P. Parikh, and J. von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 21 2008 3543 3551
9. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 5578 2002 63 64
10. D.J. Slamon, B. Leyland-Jones, and S. Shak et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783 792
11. S.G. O'Brien, F. Guilhot, and R.A. Larson et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 11 2003 994 1004
12. R.J. Slebos, R.E. Kibbelaar, and O. Dalesio et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 9 1990 561 565
13. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 24 2004 8919 8923
14. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 2009 947 957
15. R. Govindan, L. Ding, and M. Griffith et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers Cell 150 6 2012 1121 1134
16. M. Imielinski, A.H. Berger, and P.S. Hammerman et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 6 2012 1107 1120
17. L. Ding, G. Getz, and D.A. Wheeler et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 7216 2008 1069 1075
18. R. Govindan, P.S. Hammerman, and D.N. Hayes et al. Comprehensive genomic characterization of squamous cell carcinoma of the lung ASCO Meeting Abstracts 30 15 suppl 2012 7006
19. P.K. Paik, A. Hasanovic, L. Wang, N. Rekhtman, M. Ladanyi, and M.G. Kris Multiplex testing for driver mutations in squamous cell carcinomas of the lung ASCO Meeting Abstracts 30 15 suppl 2012 7505
20. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-525.
21. L.V. Sequist, R.S. Heist, and A.T. Shaw et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice Ann Oncol 22 12 2011 2616 2624
22. M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 7153 2007 561 566
23. E.L. Kwak, Y.J. Bang, and D.R. Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 18 2010 1693 1703
24. K. Pulford, L. Lamant, and E. Espinos et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase Cell Mol Life Sci 61 23 2004 2939 2953
25. J.L. Kutok, and J.C. Aster Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma J Clin Oncol 20 17 2002 3691 3702
26. R. Wang, Y. Pan, and C. Li et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers Clin Cancer Res 18 17 2012 4725 4732
27. H.R. Sanders, H.R. Li, and J.M. Bruey et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer Cancer Genet 204 1 2011 45 52
28. C.M. Conklin, K.J. Craddock, C. Have, J. Laskin, C. Couture, and D.N. Ionescu Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent J Thorac Oncol 8 1 2013 45 51
29. K. Tuononen, V.K. Sarhadi, and A. Wirtanen et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods Biomed Res Int 2013 2013:757490
30. E.S. Yi, J.M. Boland, and J.J. Maleszewski et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 3 2011 459 465
31. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 26 2009 4247 4253
32. S.J. Rodig, M. Mino-Kenudson, and S. Dacic et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population Clin Cancer Res 15 16 2009 5216 5223
33. C. Santelmo, A. Ravaioli, and E. Barzotti et al. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib Lung Cancer 81 2 2013 294 296
34. D.R. Camidge, Y.J. Bang, and E.L. Kwak et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 10 2012 1011 1019
35. A.T. Shaw, B.Y. Yeap, and B.J. Solomon et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 11 2011 1004 1012
36. D.-W. Kim, M.-J. Ahn, and Y. Shi et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts 30 15 suppl 2012 7533
37. A.T. Shaw, D.W. Kim, and K. Nakagawa et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 25 2013 2385 2394
38. A.J. Weickhardt, R.C. Doebele, and W.T. Purcell et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients Cancer 119 13 2013 2383 2390
39. Y.L. Choi, M. Soda, and Y. Yamashita et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N Engl J Med 363 18 2010 1734 1739
40. R. Katayama, A.T. Shaw, and T.M. Khan et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers Sci Transl Med 4 120 2012 120ra17
41. R.C. Doebele, A.B. Pilling, and D.L. Aisner et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 5 2012 1472 1482
42. T. Sasaki, J. Koivunen, and A. Ogino et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors Cancer Res 71 18 2011 6051 6060
43. J. Tanizaki, I. Okamoto, and T. Okabe et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer Clin Cancer Res 18 22 2012 6219 6226
44. D.R. Camidge, L. Bazhenova, and R. Salgia et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results ASCO Meeting Abstracts 31 15 suppl 2013 8031
45. A.T. Shaw, R. Mehra, and D.-W. Kim et al. Clinical activity of the ALK inhibitor LDK378 in advanced ALK-positive NSCLC. ASCO Meeting Abstracts 31 15 suppl 2013 8010
46. T. Seto, K. Kiura, and M. Nishio et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study Lancet Oncol 14 7 2013 590 598
47. S.H. Ou, S.M. Gadgeel, and A. Chiappori et al. Safety and efficacy analysis of alectinib (CH424802/RO542802) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotnib in a dose-finding phase I study 2013 European Society of Medical Oncology Annual Meeting Abstracts 2013 Abstract # 44 LBA
48. K.D. Davies, and R.C. Doebele Molecular pathways: ROS1 fusion proteins in cancer Clin Cancer Res 19 15 2013 4040 4045
49. C. Birchmeier, S. Sharma, and M. Wigler Expression and rearrangement of the ROS1 gene in human glioblastoma cells Proc Natl Acad Sci U S A 84 24 1987 9270 9274
50. K. Bergethon, A.T. Shaw, and S.H. Ou et al. ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 8 2012 863 870
51. C. Li, R. Fang, and Y. Sun et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers PLoS One 6 11 2011 e28204
52. K.D. Davies, A.T. Le, and M.F. Theodoro et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin Cancer Res 18 17 2012 4570 4579
53. K. Takeuchi, M. Soda, and Y. Togashi et al. RET, ROS1 and ALK fusions in lung cancer Nat Med 18 3 2012 378 381
54. V.M. Rimkunas, K.E. Crosby, and D. Li et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion Clin Cancer Res 18 16 2012 4449 4457
55. J. Acquaviva, R. Wong, and A. Charest The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer Biochim Biophys Acta 1795 1 2009 37 52
56. I.M. El-Deeb, B.S. Park, and S.J. Jung et al. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors Bioorg Med Chem Lett 19 19 2009 5622 5626
57. E. Sonnenberg-Riethmacher, B. Walter, D. Riethmacher, S. Godecke, and C. Birchmeier The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis Genes Dev 10 10 1996 1184 1193
58. U. McDermott, A.J. Iafrate, and N.S. Gray et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res 68 9 2008 3389 3395
59. A.T. Shaw, D.R. Camidge, and J.A. Engelman et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement ASCO Meeting Abstracts 30 15 suppl 2012 7508
60. M.M. Awad, R. Katayama, and M. McTigue et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1 N Engl J Med 368 25 2013 2395 2401
61. K.D. Davies, S. Mahale, and D.P. Astling et al. Resistence to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer PLoS One 8 12 2013 e82236
62. R.M. Squillace, R. Anjum, and D. Miller et al. AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions AACR Ann. Meeting Abstracts 2013 5655
63. M.A. Davare, A. Saborowski, and C.A. Eide et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins Proc Natl Acad Sci U S A 110 48 2013 19519 19524
64. E. Santos, D. Martin-Zanca, E.P. Reddy, M.A. Pierotti, G. Della Porta, and M. Barbacid Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient Science 223 4637 1984 661 664
65. M.G. Kris, B.E. Johnson, and D.J. Kwiatkowski et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC) ASCO Meeting Abstracts 29 18 suppl 2011 CRA7506
66. G.J. Riely, M.G. Kris, and D. Rosenbaum et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Clin Cancer Res 14 18 2008 5731 5734
67. Y. Sun, Y. Ren, and Z. Fang et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases J Clin Oncol 28 30 2010 4616 4620
68. C. Mascaux, N. Iannino, and B. Martin et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 1 2005 131 139
69. F.A. Shepherd, C. Domerg, and P. Hainaut et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol 31 17 2013 2173 2181
70. A.A. Adjei, A. Mauer, and L. Bruzek et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer J Clin Oncol 21 9 2003 1760 1766
71. E.F. Smit, A.M. Dingemans, F.B. Thunnissen, M.M. Hochstenbach, R.J. van Suylen, and P.E. Postmus Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report J Thorac Oncol 5 5 2010 719 720
72. C. Printz BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery Cancer 116 14 2010 3307 3308
73. P.A. Janne, A.T. Shaw, and J.R. Pereira et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 1 2013 38 47
74. G.R. Blumenschein, E.F. Smit, and D. Planchard et al. MEK114653: a randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts 31 15 suppl 2013 8029
75. D.R. Gandara, S. Hiret, and G.R. Blumenschein et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a phase I/Ib trial ASCO Meeting Abstracts 31 15 suppl 2013 8028
76. L.N. Klapper, S. Glathe, and N. Vaisman et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proc Natl Acad Sci U S A 96 9 1999 4995 5000
77. D. Karunagaran, E. Tzahar, and R.R. Beerli et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer EMBO J 15 2 1996 254 264
78. C.R. King, M.H. Kraus, and S.A. Aaronson Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 4717 1985 974 976
79. C.E. Geyer, J. Forster, and D. Lindquist et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 26 2006 2733 2743
80. Y.J. Bang, E. Van Cutsem, and A. Feyereislova et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial Lancet 376 9742 2010 687 697
81. F.R. Hirsch, M. Varella-Garcia, and W.A. Franklin et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas Br J Cancer 86 9 2002 1449 1456
82. P. Heinmoller, C. Gross, and K. Beyser et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin Clin Cancer Res 9 14 2003 5238 5243
83. T. Shimamura, H. Ji, and Y. Minami et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272 Cancer Res 66 13 2006 6487 6491
84. P. Stephens, C. Hunter, and G. Bignell et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 7008 2004 525 526
85. H. Shigematsu, T. Takahashi, and M. Nomura et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas Cancer Res 65 5 2005 1642 1646
86. L. Liu, X. Shao, and W. Gao et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data J Thorac Oncol 5 12 2010 1922 1932
87. S.E. Wang, A. Narasanna, and M. Perez-Torres et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors Cancer Cell 10 1 2006 25 38
88. U. Gatzemeier, G. Groth, and C. Butts et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ann Oncol 15 1 2004 19 27
89. H.J. Ross, G.R. Blumenschein Jr., and J. Aisner et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer Clin Cancer Res 16 6 2010 1938 1949
90. J. Mazieres, S. Peters, and B. Lepage et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives J Clin Oncol 31 16 2013 1997 2003
91. H. Davies, G.R. Bignell, and C. Cox et al. Mutations of the BRAF gene in human cancer Nature 417 6892 2002 949 954
92. S.T. Yuen, H. Davies, and T.L. Chan et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res 62 22 2002 6451 6455
93. E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, and J.A. Fagin High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res 63 7 2003 1454 1457
94. K.T. Flaherty, I. Puzanov, and K.B. Kim et al. Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 9 2010 809 819
95. K. Naoki, T.H. Chen, W.G. Richards, D.J. Sugarbaker, and M. Meyerson Missense mutations of the BRAF gene in human lung adenocarcinoma Cancer Res 62 23 2002 7001 7003
96. A. Marchetti, L. Felicioni, and S. Malatesta et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations J Clin Oncol 29 26 2011 3574 3579
97. O. Gautschi, C. Pauli, and K. Strobel et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib J Thorac Oncol 7 10 2012 e23 e24
98. H. Yang, B. Higgins, and K. Kolinsky et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 13 2010 5518 5527
99. C.A. Pratilas, A.J. Hanrahan, and E. Halilovic et al. Genetic predictors of MEK dependence in non-small cell lung cancer Cancer Res 68 22 2008 9375 9383
100. K.T. Flaherty, C. Robert, and P. Hersey et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2 2012 107 114
101. M. Santoro, G. Chiappetta, and A. Cerrato et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice Oncogene 12 8 1996 1821 1826
102. M. Santoro, F. Carlomagno, and A. Romano et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B Science 267 5196 1995 381 383
103. T. Kohno, H. Ichikawa, and Y. Totoki et al. KIF5B-RET fusions in lung adenocarcinoma Nat Med 18 3 2012 375 377
104. D. Lipson, M. Capelletti, and R. Yelensky et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nat Med 18 3 2012 382 384
105. M. Varella-Garcia, L.G. Xu, and S. Mahale et al. RET rearrangements detected by FISH in "pan-negative" lung adenocarcinoma ASCO Meeting Abstracts 31 15 suppl 2013 8024
106. M. Suzuki, H. Makinoshima, and S. Matsumoto et al. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo Cancer Sci 104 7 2013 896 903
107. A. Drilon, L. Wang, and A. Hasanovic et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas Cancer Discov 3 6 2013 630 635
108. R. Wang, H. Hu, and Y. Pan et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer J Clin Oncol 30 35 2012 4352 4359
109. R. Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, and T. Mitsudomi Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers J Thorac Oncol 4 1 2009 5 11
110. M. Beau-Faller, A.M. Ruppert, and A.C. Voegeli et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort J Thorac Oncol 3 4 2008 331 339
111. J. Bean, C. Brennan, and J.Y. Shih et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 52 2007 20932 20937
112. E. Gherardi, W. Birchmeier, C. Birchmeier, G. Vande Woude, and M.E.T. Targeting in cancer: rationale and progress Nat Rev Cancer 12 2 2012 89 103
113. M. Kong-Beltran, S. Seshagiri, and J. Zha et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer Cancer Res 66 1 2006 283 289
114. J.S. Seo, Y.S. Ju, and W.C. Lee et al. The transcriptional landscape and mutational profile of lung adenocarcinoma Genome Res 22 11 2012 2109 2119
115. D.R. Spigel, T.J. Ervin, and R.A. Ramlau et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer J Clin Oncol 31 32 2013 4105 4114
116. L.V. Sequist, J. von Pawel, and E.G. Garmey et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J Clin Oncol 29 24 2011 3307 3315
117. H.Y. Zou, Q. Li, and J.H. Lee et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res 67 9 2007 4408 4417
118. S.H. Ou, E.L. Kwak, and C. Siwak-Tapp et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification J Thorac Oncol 6 5 2011 942 946
119. J.E. Chaft, M.E. Arcila, and P.K. Paik et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling Mol Cancer Ther 11 2 2012 485 491
120. O. Kawano, H. Sasaki, and K. Okuda et al. PIK3CA gene amplification in Japanese non-small cell lung cancer Lung Cancer 58 1 2007 159 160
121. P.S. Hammerman, M.L. Sos, and A.H. Ramos et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 1 1 2011 78 89
122. F.M. Johnson, B.N. Bekele, and L. Feng et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer J Clin Oncol 28 30 2010 4609 4615
123. G.V. Scagliotti, and S. Novello The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors Cancer Treat Rev 38 4 2012 292 302
124. A.J. Casa, R.K. Dearth, B.C. Litzenburger, A.V. Lee, and X. Cui The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance Front Biosci 13 2008 3273 3287
125. D.D. Karp, L.G. Paz-Ares, and S. Novello et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 15 2009 2516 2522
126. A. Dutt, A.H. Ramos, and P.S. Hammerman et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer PLoS One 6 6 2011 e20351
127. M.J. Ratain, G.K. Schwartz, and A.M. Oza et al. Brivanib (BMS-582664) in advanced solid tumors (AST):Results of a phase II randomized discontinuation trial (RDT) ASCO Meeting Abstracts 29 15 suppl 2011 3079
128. R.G. Liao, J. Jung, and J. Tchaicha et al. Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma Cancer Res 73 16 2013 5195 5205
129. Y.M. Wu, F. Su, and S. Kalyana-Sundaram et al. Identification of targetable FGFR gene fusions in diverse cancers Cancer Discov 3 6 2013 636 647
130. I.J. Majewski, L. Mittempergher, and N.M. Davidson et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing J Pathol 230 3 2013 270 276
131. A. Greco, C. Miranda, S. Pagliardini, L. Fusetti, I. Bongarzone, and M.A. Pierotti Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes Genes Chromosomes Cancer 19 2 1997 112 123
132. M.V. Chao, R. Rajagopal, and F.S. Lee Neurotrophin signalling in health and disease Clin Sci (Lond) 110 2 2006 167 173
133. D. Martin-Zanca, S.H. Hughes, and M. Barbacid A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences Nature 319 6056 1986 743 748
134. R.C. Doebele, A. Vaishnavi, and M. Capelletti et al. NTRK1 gene fusions as a novel oncogene target in lung cancer ASCO Meeting Abstracts 31 15 suppl 2013 8023
135. A. Vaishnavi, M. Capelletti, and A.T. Le et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer Nat Med 19 11 2013 1469 1472
136. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers Targeting the dynamic HSP90 complex in cancer Nat Rev Cancer 10 8 2010 537 549
137. T. Mok, Y.L. Wu, and J.S. Lee et al. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: a randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C) ASCO Meeting Abstracts 31 15 suppl 2013 8021
138. E. Pailler, J. Adam, and A. Barthelemy et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer J Clin Oncol 31 18 2013 2273 2281
139. H. Mano ALKoma: a cancer subtype with a shared target Cancer Discov 2 6 2012 495 502